Cancer screening in patients infected with HIV
- PMID: 21695529
- PMCID: PMC3307131
- DOI: 10.1007/s11904-011-0085-5
Cancer screening in patients infected with HIV
Abstract
Non-AIDS-defining cancers are a rising health concern among HIV-infected patients. Cancer screening is now an important component of health maintenance in HIV clinical practice. The decision to screen an HIV-infected patient for cancer should include an assessment of individualized risk for the particular cancer, life expectancy, and the harms and benefits associated with the screening test and its potential outcome. HIV-infected patients are at enhanced risk of several cancers compared to the general population; anal cancer, hepatocellular carcinoma, Hodgkin's lymphoma, and lung cancer all have good evidence demonstrating an enhanced risk in HIV-infected persons. A number of cancer screening interventions have shown benefit for specific cancers in the general population, but data on the application of these tests to HIV-infected persons are limited. Here we review the epidemiology and background literature relating to cancer screening interventions in HIV-infected persons. We then use these data to inform a conceptual model for evaluating HIV-infected patients for cancer screening.
Conflict of interest statement
Figures
Similar articles
-
Screening guidelines for non-AIDS defining cancers in HIV-infected individuals.Curr Opin Oncol. 2013 Sep;25(5):518-25. doi: 10.1097/CCO.0b013e328363e04a. Curr Opin Oncol. 2013. PMID: 23942295 Free PMC article. Review.
-
Cancer screening in women living with HIV infection.Womens Health (Lond). 2017 Dec;13(3):68-79. doi: 10.1177/1745505717731970. Epub 2017 Sep 27. Womens Health (Lond). 2017. PMID: 28952428 Free PMC article.
-
Non-AIDS-defining cancer in HIV-infected people.Hematol Oncol Clin North Am. 2003 Jun;17(3):889-99. doi: 10.1016/s0889-8588(03)00038-8. Hematol Oncol Clin North Am. 2003. PMID: 12852661 Review.
-
Benefits and harms of lung cancer screening in HIV-infected individuals with CD4+ cell count at least 500 cells/μl.AIDS. 2018 Jun 19;32(10):1333-1342. doi: 10.1097/QAD.0000000000001818. AIDS. 2018. PMID: 29683843 Free PMC article.
-
Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection.Trials. 2021 Nov 27;22(1):851. doi: 10.1186/s13063-021-05777-6. Trials. 2021. PMID: 34838115 Free PMC article. Clinical Trial.
Cited by
-
The effect of non-AIDS-defining cancers on people living with HIV.Lancet Oncol. 2021 Jun;22(6):e240-e253. doi: 10.1016/S1470-2045(21)00137-6. Lancet Oncol. 2021. PMID: 34087151 Free PMC article. Review.
-
Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study.Cancer Epidemiol Biomarkers Prev. 2024 Aug 1;33(8):1057-1064. doi: 10.1158/1055-9965.EPI-24-0137. Cancer Epidemiol Biomarkers Prev. 2024. PMID: 38713162 Free PMC article.
-
An increased risk for fractures: another cause of frailty in HIV-infected subjects.Endocrine. 2012 Jun;41(3):347-9. doi: 10.1007/s12020-012-9640-0. Endocrine. 2012. PMID: 22399153 No abstract available.
-
Hepatitis C virus infection among HIV-positive men who have sex with men: protocol for a systematic review and meta-analysis.Syst Rev. 2014 Mar 26;3:31. doi: 10.1186/2046-4053-3-31. Syst Rev. 2014. PMID: 24669911 Free PMC article.
-
Knowledge, attitudes and practices of AIDS associated malignancies among people living with HIV in Nigeria.Infect Agent Cancer. 2012 Oct 25;7(1):28. doi: 10.1186/1750-9378-7-28. Infect Agent Cancer. 2012. PMID: 23098099 Free PMC article.
References
-
- Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic) J Acquir Immune Defic Syndr. 2008;48:590–598. - PubMed
-
- Phillips AA, Justman JE. Screening HIV-infected patients for non-AIDS-defining malignancies. Curr HIV/AIDS Rep. 2009;6:83–92. - PubMed
-
-
Braithwaite RS, Fiellin D, Justice AC. The payoff time: a flexible framework to help clinicians decide when patients with comorbid disease are not likely to benefit from practice guidelines. Med Care. 2009;47:610–617. This article describes "payoff time," a conceptual approach to tailoring cancer screening guidelines to patients with significant comorbid illness.
-
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical